Please check your internet connection and try again.
## Ecospirin Enteric-Coated Aspirin
**Overview:**
Ecospirin is a brand name for enteric-coated aspirin. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and antiplatelet properties. The enteric coating is designed to delay the release of aspirin until it reaches the small intestine, potentially reducing gastric irritation.
**Primary Indications:**
* Pain relief (mild to moderate)
* Fever reduction
* Antiplatelet therapy (e.g., prevention of cardiovascular events, secondary prevention after myocardial infarction or stroke)
**Adult Dosing:**
* **Analgesia/Antipyresis:** 325 mg to 650 mg orally every 4 to 6 hours as needed. Maximum daily dose typically 4000 mg.
* **Antiplatelet Therapy:**
* **Primary Prevention:** 75 mg to 100 mg orally once daily.
* **Secondary Prevention:** 75 mg to 325 mg orally once daily. Dosing may vary based on specific indication and physician preference.
**Pediatric Dosing:**
* **Analgesia/Antipyresis:** Dosing is typically based on weight. A common dose is 10 mg/kg/dose to 15 mg/kg/dose orally every 4 to 6 hours. Maximum pediatric dose is generally 4000 mg/day.
* **Reye's Syndrome:** Aspirin is contraindicated in children and adolescents with viral infections (e.g., influenza, chickenpox) due to the risk of Reye's syndrome.
**Dose Adjustments:**
No specific dose adjustments are typically required for renal or hepatic impairment, but caution is advised in severe dysfunction due to potential for accumulation and increased risk of adverse effects.
**Contraindications:**
* Hypersensitivity to aspirin, salicylates, or NSAIDs.
* Asthma, urticaria, or allergic-type reactions triggered by aspirin or other NSAIDs.
* Active peptic ulceration or gastrointestinal bleeding.
* Children and adolescents with viral infections (risk of Reye's syndrome).
* Late pregnancy (third trimester).
* Hemophilia and other bleeding disorders.
**Adverse Effects:**
* **Gastrointestinal:** Dyspepsia, heartburn, nausea, vomiting, abdominal pain, occult blood loss, erosions, ulcers, bleeding, perforation.
* **Hematologic:** Increased bleeding time, thrombocytopenia, bruising.
* **Ototoxicity:** Tinnitus, hearing loss (usually with higher doses).
* **Hypersensitivity:** Bronchospasm, urticaria, angioedema.
* **Renal:** Renal impairment, interstitial nephritis.
* **Hepatic:** Elevated liver enzymes, hepatic dysfunction.
* **Reye's Syndrome:** In children and adolescents with viral illnesses.
**Key Drug Interactions:**
* **Anticoagulants (e.g., warfarin, heparin):** Increased risk of bleeding.
* **Other NSAIDs and COX-2 inhibitors:** Increased risk of GI toxicity and bleeding.
* **Corticosteroids:** Increased risk of GI toxicity.
* **Antihypertensives (e.g., ACE inhibitors, ARBs, diuretics):** May reduce antihypertensive efficacy; increased risk of renal dysfunction.
* **Methotrexate:** Increased methotrexate toxicity.
* **Sulfonylureas:** May enhance hypoglycemic effect.
* **Uricosuric agents:** May reduce efficacy.
* **Alcohol:** Increased risk of GI bleeding.
**Monitoring:**
* Signs and symptoms of GI bleeding (melena, hematemesis, abdominal pain).
* Signs and symptoms of bleeding elsewhere (bruising, epistaxis, prolonged bleeding from cuts).
* Renal function (especially in patients with pre-existing renal disease or those taking other nephrotoxic agents).
* Liver function (less commonly required, but monitor with long-term high-dose therapy).
* Tinnitus or hearing changes.
**Clinical Pearls:**
* The enteric coating may delay absorption, so onset of action for pain/fever may be slower compared to non-coated formulations.
* While the enteric coating may reduce gastric irritation, it does not eliminate the risk of GI bleeding or ulceration.
* For acute situations requiring rapid platelet inhibition (e.g., acute coronary syndrome), immediate-release aspirin is preferred.
* Patients should be advised to avoid concurrent use of alcohol to minimize GI risk.
* Discontinuation of aspirin should be considered prior to elective surgery, with the duration of discontinuation dependent on the surgical procedure and bleeding risk.
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines for definitive patient management.*
